These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17152500)

  • 41. Gefitinib therapy for non-small cell lung cancer.
    Birnbaum A; Ready N
    Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
    Veronese ML; Algazy K; Bearn L; Eaby B; Alavi J; Evans T; Stevenson JP; Shults J
    Cancer Invest; 2005; 23(4):296-302. PubMed ID: 16100941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
    Lee DH; Han JY; Lee HG; Lee JJ; Lee EK; Kim HY; Kim HK; Hong EK; Lee JS
    Clin Cancer Res; 2005 Apr; 11(8):3032-7. PubMed ID: 15837758
    [TBL] [Abstract][Full Text] [Related]  

  • 44. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.
    Yin YM; Geng YT; Shao YF; Hu XL; Li W; Shu YQ; Wang ZX
    J Exp Clin Cancer Res; 2010 Sep; 29(1):126. PubMed ID: 20843324
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
    Wu YL; Fukuoka M; Mok TS; Saijo N; Thongprasert S; Yang JC; Chu DT; Yang JJ; Rukazenkov Y
    Lung Cancer; 2013 Aug; 81(2):280-7. PubMed ID: 23540718
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
    Yokouchi H; Yamazaki K; Kinoshita I; Konishi J; Asahina H; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M
    BMC Cancer; 2007 Mar; 7():51. PubMed ID: 17374153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
    Kris MG; Natale RB; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Kelly K; Spiridonidis H; Sandler A; Albain KS; Cella D; Wolf MK; Averbuch SD; Ochs JJ; Kay AC
    JAMA; 2003 Oct; 290(16):2149-58. PubMed ID: 14570950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
    Hirose T; Fujita K; Kusumoto S; Oki Y; Murata Y; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ohmori T; Sasaki Y
    Lung Cancer; 2016 Mar; 93():69-76. PubMed ID: 26898617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Efficacy and safety of gefitinib monotherapy for Chinese elderly patients with advanced non-small cell lung cancer].
    Zhang L; Wang SL; Zhang XT; Li LY; Wang MZ
    Zhonghua Nei Ke Za Zhi; 2007 May; 46(5):392-5. PubMed ID: 17637309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
    Takahashi K; Saito H; Hasegawa Y; Ando M; Yamamoto M; Kojima E; Sugino Y; Kimura T; Nomura F; Ogasawara T; Shindoh J; Yoshida N; Suzuki R
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):721-7. PubMed ID: 25087097
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.
    Xu JM; Han Y; Li YM; Zhao CH; Wang Y; Paradiso A
    BMC Cancer; 2006 Dec; 6():288. PubMed ID: 17173694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
    Cho BC; Im CK; Park MS; Kim SK; Chang J; Park JP; Choi HJ; Kim YJ; Shin SJ; Sohn JH; Kim H; Kim JH
    J Clin Oncol; 2007 Jun; 25(18):2528-33. PubMed ID: 17577030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
    Inoue A; Suzuki T; Fukuhara T; Maemondo M; Kimura Y; Morikawa N; Watanabe H; Saijo Y; Nukiwa T
    J Clin Oncol; 2006 Jul; 24(21):3340-6. PubMed ID: 16785471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
    Yang CH; Yu CJ; Shih JY; Chang YC; Hu FC; Tsai MC; Chen KY; Lin ZZ; Huang CJ; Shun CT; Huang CL; Bean J; Cheng AL; Pao W; Yang PC
    J Clin Oncol; 2008 Jun; 26(16):2745-53. PubMed ID: 18509184
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Gefitinib target treatment in non-small cell lung cancer].
    Wu YL; Yang JJ; Lin JY; Huang YJ; Liao RQ; Huang YS; Zhou Q; Xu CR; Wang Z
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):98-102. PubMed ID: 17445469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
    Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
    J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer].
    Wang MZ; Zhong W; Zhang L; Li LY; Wang SL; Li JR; Zhang XT
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):221-4. PubMed ID: 18756941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
    Mohamed MK; Ramalingam S; Lin Y; Gooding W; Belani CP
    Ann Oncol; 2005 May; 16(5):780-5. PubMed ID: 15728108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
    Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
    BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.